Listed

AMN Healthcare Services Inc: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 6, 2023 and accepted by EDGAR at Nov 3, 2023, 19:58 ET.

Share

Management's discussion and analysis

As filed, 43,830 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere herein and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on February 22, 2023 (“2022 Annual Report”). Certain statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements.” We undertake no obligation to update the forward-looking statements in this Quarterly Report. References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries.

Overview of Our Business

We provide technology-enabled healthcare workforce solutions and staffing services to healthcare organizations across the nation. As an innovative total talent solutions partner, our managed services programs, or “MSP,” vendor management systems, or “VMS,” workforce consulting services, predictive modeling, staff scheduling, revenue cycle solutions, language services, and the placement of physicians, nurses, allied healthcare professionals and healthcare leaders into temporary and permanent positions enable our clients to successfully reduce staffing complexity, increase efficiency and lead their organizations within the rapidly evolving healthcare environment.

We conduct business through three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. For the three months ended September 30, 2023, we recorded revenue of $853.5 million, as compared to $1,138.6 million for the same period last year. For the nine months ended September 30, 2023, we recorded revenue of $2,971.0 million, as compared to $4,117.7 million for the same period last year.

Nurse and allied solutions segment revenue comprised 70% and 77% of total consolidated revenue for the nine months ended September 30, 2023 and 2022, respectively. Through our nurse and allied solutions segment, we provide hospitals and other healthcare facilities with a comprehensive managed services solution in which we manage and staff all the temporary and permanent nursing and allied staffing needs of a client. We also provide revenue cycle solutions, which include skilled labor solutions for remote medical coding, clinical documentation improvement, case management, and clinical data registry, and provide auditing and advisory services. A majority of our placements in this segment are under our managed services solution, however, we also provide traditional direct nurse and allied healthcare staffing solutions of variable assignment lengths.

Physician and leadership solutions segment revenue comprised 17% and 13% of total consolidated revenue for the nine months ended September 30, 2023 and 2022, respectively. Through our physician and leadership solutions segment, we place physicians of all specialties, as well as dentists and advanced practice providers, with clients on a temporary basis, generally as independent contractors. We also recruit physicians and healthcare leaders for permanent placement and place interim leaders and executives across all healthcare settings. The interim healthcare leaders and executives we place are typically placed on contracts with assignment lengths ranging from a few days to one year, and a growing number of these placements are under our managed services solution.

Technology and workforce solutions segment revenue comprised 13% and 10% of total consolidated revenue for both of the nine months ended September 30, 2023 and 2022, respectively. Through our technology and workforce solutions segment, we provide hospitals and other healthcare facilities with a range of workforce solutions, including: (1) language services, (2) software-as-a-service (“SaaS”) VMS technologies through which our clients can manage their temporary staffing needs, (3) workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology, (4) recruitment process outsourcing services that leverage our expertise and support systems to replace or complement a client’s existing internal recruitment function for permanent placement needs, and (5) virtual care services.

Operating Metrics

In addition to our consolidated and segment financial results, we monitor the following key metrics to help us evaluate our results of operations and financial condition and make strategic decisions. We believe this information is useful in understanding our operational performance and trends affecting our businesses.

  • Average travelers on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period, which is used by management as a measure of volume in our nurse and allied solutions segment;
  • Bill rates represent the hourly straight-time rates that we bill to clients, which are an indicator of labor market trends and costs within our nurse and allied solutions segment;
  • Billable hours represent hours worked by our healthcare professionals that we are able to bill on client engagements, which are used by management as a measure of volume in our nurse and allied solutions segment;
  • Days filled is calculated by dividing total locum tenens hours filled during the period by eight hours, which is used by management as a measure of volume in our locum tenens business within our physician and leadership solutions segment;
  • Revenue per day filled is calculated by dividing revenue of our locum tenens business by days filled for the period, which is an indicator of labor market trends and costs in our locum tenens business within our physician and leadership solutions segment; and
  • Minutes represent the time-based utilization of interpretation services that we are able to bill our clients, which are used by management as a measure of volume in our language services business within our technology and workforce solutions segment.

Recent Trends

Demand for our temporary and permanent placement staffing services is driven in part by U.S. economic and labor trends, and from early 2020 through 2022, the COVID-19 pandemic and the “Great Resignation” impacted demand. From late 2020 through most of 2022, these conditions resulted in historically high demand for our nurses, allied healthcare professionals and vendor-neutral VMS technologies supporting the placement of these professionals. In 2023, with the pandemic easing, demand in our travel nurse business declined significantly over the course of the first quarter and into the early second quarter. Since the low point in the early second quarter, we have seen demand increase through the early fourth quarter, although travel nurse demand has remained below pre-pandemic levels. Demand in our allied business continues to be above pre-pandemic levels, and certain specialties such as therapy and imaging are up significantly year over year, offsetting the decline in laboratory and other specialties involved in treating COVID-19 patients. Since mid-2022, healthcare organizations have hired permanent staff aggressively, enabling them to reduce what had been historically high utilization of contingent labor. Our clients accelerated initiatives designed to contain costs of their spend on contingent labor, and a number of clients reevaluated their approach in pursuit of more sustainable workforce solutions, including changing their choice of solutions and providers. We believe that aggressive permanent hiring and retention has enabled our clients to address labor shortages, though their progress has only partly resolved high levels of vacancies and staff attrition.

Bill rates in our nurse and allied solutions segment decreased year over year and quarter over quarter in the third quarter of 2023. After the pandemic, our clients have significantly fewer surprise vacancies, and most of the bill rate decrease reflects less urgent needs. We expect bill rates and clinician compensation to decrease slightly in the fourth quarter, although at a slower rate than the first three quarters of the year, and remain above pre-pandemic levels in 2023.

In our physician and leadership solutions segment, demand for our locum tenens business is well above pre-pandemic levels. We have seen several years of growth in certified registered nurse anesthetists (CRNAs), the specialty that represents the largest percentage of revenue in this business. The increase in demand drove a double digit increase to revenue per day filled in the third quarter as compared to the prior year. We expect strong demand for locum tenens staffing to continue but with a seasonal dip in the fourth quarter of 2023. Demand has been declining in our interim leadership and executive search businesses since the second half of 2022 as some healthcare organizations streamlined leadership roles, deferred hiring decisions, or increased permanent staff hiring.

In our technology and workforce solutions segment, our language services business continued to experience increased utilization and shift to more virtual interpretation. Bill rates and volumes in our VMS business followed similar trends, although to a greater extent, as our nurse and allied solutions segment, declining from historic highs. We anticipate bill rates and volumes in our VMS business to decrease slightly in the fourth quarter and remain above pre-pandemic levels in 2023.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, contingent consideration (“earn-out”) liabilities associated with acquisitions, and income taxes. We base these estimates on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. If these estimates differ significantly from actual results, our consolidated financial statements and future results of operations may be materially impacted. There have been no material changes in our critical accounting policies and estimates, other than the adoption of the Accounting Standard Update (“ASU”)

described in the accompanying Note (1), “Basis of Presentation,” as compared to the critical accounting policies and estimates described in our 2022 Annual Report.

Results of Operations

The following table sets forth, for the periods indicated, selected unaudited condensed consolidated statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. The Connetics acquisition impacts the comparability of the results between the nine months ended September 30, 2023 and 2022. See additional information in the accompanying Note (2), “Acquisitions.” Our historical results are not necessarily indicative of our future results of operations.

Unaudited Condensed Consolidated Statements of Operations:

Three Months Ended September 30, 2023 2022 Nine Months Ended September 30, 2023 2022
Revenue 100.0% 100.0% 100.0% 100.0%
Cost of revenue 66.1 66.2 66.7 67.4
Gross profit 33.9 33.8 33.3 32.6
Selling, general and administrative 19.1 18.9 19.2 17.4
Depreciation and amortization 4.6 2.9 3.9 2.4
Income from operations 10.2 12.0 10.2 12.8
Interest expense, net, and other 1.4 0.8 1.1 0.7
Income before income taxes 8.8 11.2 9.1 12.1
Income tax expense 2.6 3.1 2.4 3.3
Net income 6.2% 8.1% 6.7% 8.8%

Comparison of Results for the Three Months Ended September 30, 2023 to the Three Months Ended September 30, 2022

Revenue. Revenue decreased 25% to $853.5 million for the three months ended September 30, 2023 from $1,138.6 million for the same period in 2022, attributable to a decline in revenue across our segments with the greatest decline in our nurse and allied solutions segment.

Nurse and allied solutions segment revenue decreased 31% to $573.4 million for the three months ended September 30, 2023 from $828.3 million for the same period in 2022. The $254.9 million decrease was primarily attributable to a 19% decrease in the average number of travelers on assignment, an approximately 10% decrease in the average bill rate, a 4% decrease in billable hours, and an approximately $19.0 million decrease in labor disruption revenue during the three months ended September 30, 2023.

Physician and leadership solutions segment revenue decreased 9% to $159.6 million for the three months ended September 30, 2023 from $175.2 million for the same period in 2022. The $15.6 million decrease was attributable to lower revenue in our interim leadership, physician permanent placement and executive search businesses, which was partially offset by higher revenue in our locum tenens business. Revenue in our locum tenens business grew approximately 6% during the three months ended September 30, 2023 primarily due to a 15% increase in the revenue per day filled, partially offset by a 7% decrease in the number of days filled. Our interim leadership business experienced a 35% decline and our physician permanent placement and executive search businesses declined 25% during the three months ended September 30, 2023, primarily due to lower demand.

Technology and workforce solutions segment revenue decreased 11% to $120.5 million for the three months ended September 30, 2023 from $135.1 million for the same period in 2022. The $14.6 million decrease was primarily attributable to a decline within our VMS business, partially offset by growth within our language services business. Revenue for our VMS business declined 37% for similar reasons as nurse and allied solutions segment revenue, while our language services business grew 20% primarily due to a 24% increase in minutes during the three months ended September 30, 2023.

For the three months ended September 30, 2023 and 2022, revenue under our MSP arrangements comprised approximately 51% and 61% of our consolidated revenue, 70% and 79% of our nurse and allied solutions segment revenue, 19% and 18% of our physician and leadership solutions segment revenue, and 2% and 2% of our technology and workforce solutions segment revenue, respectively.

Gross Profit. Gross profit decreased 25% to $289.5 million for the three months ended September 30, 2023 from $385.0 million for the same period in 2022, representing gross margins of 33.9% and 33.8%, respectively. The increase in consolidated gross margin for the three months ended September 30, 2023, as compared to the same period in 2022, was primarily due to (1) a change in sales mix resulting from lower revenue in our nurse and allied solutions segment and (2) a higher margin in our nurse and allied solutions segment driven by lower clinician compensation. The overall increase was partially offset by a lower margin in our technology and workforce solutions segment primarily due to a change in sales mix resulting from lower revenue in our VMS business and its higher margins as compared to our other businesses within the segment. Gross margin by reportable segment for the three months ended September 30, 2023 and 2022 was 27.5% and 27.0% for nurse and allied solutions, 33.4% and 34.0% for physician and leadership solutions, and 65.0% and 75.6% for technology and workforce solutions, respectively.

Selling, General and Administrative Expenses. Selling, general and administrative (“SG&A”) expenses were $163.4 million, representing 19.1% of revenue, for the three months ended September 30, 2023, as compared to $215.4 million, representing 18.9% of revenue, for the same period in 2022. The decrease in SG&A expenses was primarily due to $30.0 million of lower employee compensation and benefits (inclusive of share-based compensation), a $10.4 million decrease in the provision for expected credit losses, and a $6.6 million decrease in professional services, legal and other expenses. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

(In Thousands)

Three Months Ended September 30, 2023 2022
Nurse and allied solutions $74,981 $108,163
Physician and leadership solutions 31,697 35,596
Technology and workforce solutions 29,225 32,127
Unallocated corporate overhead 27,196 34,635
Share-based compensation 306 4,898
$163,405 $215,419

Depreciation and Amortization Expenses. Amortization expense increased 8% to $22.6 million for the three months ended September 30, 2023 from $20.9 million for the same period in 2022, primarily attributable to the reduction of useful lives of certain staffing database intangible assets. Depreciation expense (exclusive of depreciation included in cost of revenue) increased 35% to $16.6 million for the three months ended September 30, 2023 from $12.4 million for the same period in 2022, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing technology investments to support our total talent solutions initiatives and to optimize our internal front and back-office systems. Additionally, $1.6 million and $1.1 million of depreciation expense for our language services business is included in cost of revenue for the three months ended September 30, 2023 and 2022, respectively.

Interest Expense, Net, and Other. Interest expense, net, and other was $11.5 million during the three months ended September 30, 2023 as compared to $9.0 million for the same period in 2022. The increase was primarily due to a higher average debt outstanding balance during the three months ended September 30, 2023.

Income Tax Expense. Income tax expense was $22.2 million for the three months ended September 30, 2023 as compared to $35.0 million for the same period in 2022, reflecting effective income tax rates of 29% and 27% for these periods, respectively. The increase in the effective income tax rate was primarily attributable to the recognition of $1.4 million of net discrete tax expense during the three months ended September 30, 2023 compared to a $0.8 million net discrete tax expense during the same period in 2022, in relation to income before income taxes of $75.4 million and $127.4 million for the three months ended September 30, 2023 and 2022, respectively. We currently estimate our annual effective tax rate to be approximately 27% for 2023. The 29% effective tax rate for the three months ended September 30, 2023 differs from our estimated annual effective tax rate of 27% primarily due to certain discrete tax expenses recognized during the three months ended September 30, 2023, in relation to income before income taxes.

Comparison of Results for the Nine Months Ended September 30, 2023 to the Nine Months Ended September 30, 2022

Revenue. Revenue decreased 28% to $2,971.0 million for the nine months ended September 30, 2023 from $4,117.7 million for the same period in 2022, attributable to a decline in revenue across our segments with the greatest decline in our nurse and allied solutions segment.

Nurse and allied solutions segment revenue decreased 34% to $2,086.9 million for the nine months ended September 30, 2023 from $3,157.8 million for the same period in 2022. The $1,070.9 million decrease was primarily attributable to an approximately 16% decrease in the average bill rate, a 16% decrease in the average number of travelers on assignment, a 3% decrease in billable hours, and an approximately $91.0 million decrease in labor disruption revenue during the nine months ended September 30, 2023.

Physician and leadership solutions segment revenue decreased 5% to $501.5 million for the nine months ended September 30, 2023 from $530.4 million for the same period in 2022. The $28.9 million decrease was attributable to lower revenue in our interim leadership, physician permanent placement and executive search businesses, which was partially offset by higher revenue in our locum tenens business. Revenue in our locum tenens business grew approximately 5% during the nine months ended September 30, 2023 primarily due to an 11% increase in the revenue per day filled, partially offset by a 5% decrease in the number of days filled. Our interim leadership business experienced a 23% decline and our physician permanent placement and executive search businesses declined 20% during the nine months ended September 30, 2023, primarily due to lower demand.

Technology and workforce solutions segment revenue decreased 11% to $382.5 million for the nine months ended September 30, 2023 from $429.5 million for the same period in 2022. The $47.0 million decrease was primarily attributable to a decline within our VMS business, partially offset by growth within our language services business. Revenue for our VMS business declined 34% for similar reasons as nurse and allied solutions segment revenue, while our language services business grew 21% primarily due to a 25% increase in minutes during the nine months ended September 30, 2023.

For the nine months ended September 30, 2023 and 2022, revenue under our MSP arrangements comprised approximately 55% and 63% of our consolidated revenue, 73% and 80% of our nurse and allied solutions segment revenue, 20% and 17% of our physician and leadership solutions segment revenue, and 2% and 2% of our technology and workforce solutions segment revenue, respectively.

Gross Profit. Gross profit decreased 26% to $988.6 million for the nine months ended September 30, 2023 from $1,341.4 million for the same period in 2022, representing gross margins of 33.3% and 32.6%, respectively. The increase in consolidated gross margin for the nine months ended September 30, 2023, as compared to the same period in 2022, was primarily due to (1) a change in sales mix resulting from lower revenue in our nurse and allied solutions segment and (2) a higher margin in our nurse and allied solutions segment driven by a revenue mix shift within the segment. The overall increase was partially offset by a lower margin in our technology and workforce solutions segment primarily due to a change in sales mix resulting from lower revenue in our VMS business and its higher margins as compared to our other businesses within the segment. Gross margin by reportable segment for the nine months ended September 30, 2023 and 2022 was 26.6% and 26.2% for nurse and allied solutions, 34.6% and 34.4% for physician and leadership solutions, and 67.9% and 76.9% for technology and workforce solutions, respectively.

Selling, General and Administrative Expenses. SG&A expenses were $570.8 million, representing 19.2% of revenue, for the nine months ended September 30, 2023, as compared to $717.4 million, representing 17.4% of revenue, for the same period in 2022. The decrease in SG&A expenses was primarily due to $140.7 million of lower employee compensation and benefits (inclusive of share-based compensation) and a $4.7 million decrease in the provision for expected credit losses, partially offset by a $14.4 million increase in professional services, legal and other expenses. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

(In Thousands)

Nine Months Ended September 30, 2023 2022
Nurse and allied solutions $256,185 $357,585
Physician and leadership solutions 100,392 118,095
Technology and workforce solutions 90,470 100,722
Unallocated corporate overhead 108,286 116,356
Share-based compensation 15,442 24,670
$570,775 $717,428

23

Depreciation and Amortization Expenses. Amortization expense increased 9% to $66.3 million for the nine months ended September 30, 2023 from $60.8 million for the same period in 2022, primarily attributable to (1) the reduction of useful lives of certain staffing database intangible assets and (2) additional amortization expense related to the intangible assets acquired in the Connetics acquisition. Depreciation expense (exclusive of depreciation included in cost of revenue) increased 34% to $47.3 million for the nine months ended September 30, 2023 from $35.3 million for the same period in 2022, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing technology investments to support our total talent solutions initiatives and to optimize our internal front and back-office systems. Additionally, $4.2 million and $2.9 million of depreciation expense for our language services business is included in cost of revenue for the nine months ended September 30, 2023 and 2022, respectively.

Interest Expense, Net, and Other. Interest expense, net, and other was $34.0 million during the nine months ended September 30, 2023 as compared to $28.6 million for the same period in 2022. The increase was primarily due to a higher average debt outstanding balance during the nine months ended September 30, 2023.

Income Tax Expense. Income tax expense was $72.1 million for the nine months ended September 30, 2023 as compared to $137.0 million for the same period in 2022, reflecting effective income tax rates of 27% and 27% for the nine months ended September 30, 2023 and 2022, respectively.

Liquidity and Capital Resources

In summary, our cash flows were:

(In Thousands)

Nine Months Ended September 30, 2023 2022
Net cash provided by operating activities $413,295 $538,405
Net cash used in investing activities (88,762) (148,067)
Net cash used in financing activities (352,766) (415,523)

Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities and senior notes. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities.

As of September 30, 2023, (1) $95.0 million was drawn with $634.2 million of available credit under our $750.0 million secured revolving credit facility (the “Senior Credit Facility”), (2) the aggregate principal amount of our 4.625% senior notes due 2027 (the “2027 Notes”) outstanding was $500.0 million, and (3) the aggregate principal amount of our 4.000% senior notes due 2029 (the “2029 Notes”) outstanding was $350.0 million. We describe in further detail our Amended Credit Agreement (as defined below), under which the Senior Credit Facility is governed, the 2027 Notes, and the 2029 Notes in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2022 Annual Report.

As of September 30, 2023, the total of our contractual obligations under operating leases with initial terms in excess of one year was $44.2 million. We describe in further detail our operating lease arrangements in Note (9), “Commitments and Contingencies,” of this Quarterly Report and Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (5), Leases” of our 2022 Annual Report. We also have various obligations and working capital requirements, such as certain tax and legal matters, contingent consideration and other liabilities, that are recorded on our consolidated balance sheets. See additional information in the accompanying Note (7), “Fair Value Measurement,” Note (8), “Income Taxes,” Note (9), “Commitments and Contingencies,” and Note (10), “Balance Sheet Details.”

In addition to our cash requirements, we have a share repurchase program authorized by our board of directors, which does not require the purchase of any minimum number of shares and may be suspended or discontinued at any time. See additional information in the accompanying Part II, Item 2, “Unregistered Sales of Equity Securities and Use of Proceeds.” Under the repurchase program, we entered into an accelerated share repurchase (“ASR”) agreement with a counterparty on May 8, 2023 to repurchase $200.0 million of our outstanding common stock and received an initial delivery of 1.8 million shares. On August 10, 2023, we received an additional 0.3 million shares of our common stock upon settlement of the ASR agreement. The ASR was funded through borrowings under the Senior Credit Facility. See additional information in the accompanying Note (4), “Net Income Per Common Share.”

We believe that cash generated from operations and available borrowings under the Senior Credit Facility will be sufficient to fund our operations and liquidity requirements, including expected capital expenditures, for the next 12 months and beyond. We intend to finance potential future acquisitions with cash provided from operations, borrowings under the Senior Credit Facility or other borrowings under our amended credit agreement, bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.

Operating Activities

Net cash provided by operating activities for the nine months ended September 30, 2023 was $413.3 million, compared to $538.4 million for the same period in 2022. The decrease in net cash provided by operating activities was primarily attributable to (1) a decrease in net income excluding non-cash expenses of $129.0 million primarily due to a decline in operating results in our nurse and allied solutions and technology and workforce solutions segments, (2) a decrease in accounts payable and accrued expenses between periods of $154.6 million primarily due to decreased associate vendor usage, (3) a decrease in accrued compensation and benefits between periods of $81.2 million primarily due to prior year increases in pay rates and the average number of travelers on assignment in our nurse and allied solutions segment and increased employee compensation and benefits in 2022, including accrued bonuses and commissions that were paid during the first quarter of 2023, and (4) increases in prepaid expenses and other current assets between periods of $55.2 million and $8.6 million, respectively, primarily due to prepayments and deposits that were made in 2021 and refunded by third-party vendors in 2022 related to labor disruption services. The overall decrease in net cash provided by operating activities was partially offset by (1) an increase in other liabilities between periods of $152.0 million due to lower cash paid for income taxes and an increase to accrued loss contingencies in the current year, in addition to client deposits related to labor disruption services that were returned during the prior year and (2) a decrease in accounts receivable and subcontractor receivables between periods of $140.0 million primarily due to a larger decrease in the receivables balance in the current year as compared to the prior year, which was due to decreases in revenue and associate vendor usage along with timing of collections during the nine months ended September 30, 2023. Our Days Sales Outstanding (“DSO”) was 61 days at September 30, 2023, 55 days at December 31, 2022, and 59 days at September 30, 2022.

Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2023 was $88.8 million, compared to net cash used in investing activities of $148.1 million for the same period in 2022. The decrease was primarily due to (1) $69.8 million used for acquisitions during the nine months ended September 30, 2022, as compared to no cash paid for acquisitions during the nine months ended September 30, 2023, and (2) net proceeds of investments of $9.9 million during the nine months ended September 30, 2023, as compared to a net purchase of $0.6 million during the nine months ended September 30, 2022 The overall decrease was partially offset by $24.9 million of payments to fund the deferred compensation plan during the nine months ended September 30, 2023, as compared to $21.4 million of payments during the nine months ended September 30, 2022.. In addition, capital expenditures were $73.8 million and $51.2 million for the nine months ended September 30, 2023 and 2022, respectively.

Financing Activities

Net cash used in financing activities during the nine months ended September 30, 2023 was $352.8 million, primarily due to (1) $424.7 million paid in connection with the repurchase of our common stock, (2) repayments of $330.0 million under the Senior Credit Facility, (3) $11.9 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards, (4) $7.5 million for acquisition contingent consideration earn-out payments and (5) $3.6 million payment of financing costs in connection with the Third Amendment (as defined below), all of which was partially offset by borrowings of $425.0 million under the Senior Credit Facility. Net cash used in financing activities during the nine months ended September 30, 2022 was $415.5 million due to $401.9 million paid in connection with the repurchase of our common stock and $13.6 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards.

Amended Credit Agreement

On February 10, 2023, we entered into the third amendment to our credit agreement (the “Third Amendment”). The Third Amendment (together with the credit agreement as amended to date, collectively, the “Amended Credit Agreement”) provides for, among other things, an increase to the revolving commitments under the Senior Credit Facility to $750.0 million and an extension of the maturity date of the Amended Credit Agreement to February 10, 2028. Our obligations under the Amended Credit Agreement are secured by substantially all of our assets. We describe in further detail the terms of the Amended Credit Agreement, including maturity dates and interest terms, in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2022 Annual Report.

Letters of Credit

At September 30, 2023, we maintained outstanding standby letters of credit totaling $21.3 million as collateral in relation to our workers’ compensation insurance agreements and a corporate office lease agreement. Of the $21.3 million of outstanding letters of credit, we have collateralized $0.5 million in cash and cash equivalents and the remaining $20.8 million is collateralized by the Senior Credit Facility. Outstanding standby letters of credit at December 31, 2022 totaled $22.0 million.

Recent Accounting Pronouncements

There have been no new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.

Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We base these forward-looking statements on our expectations, estimates, forecasts, and projections about future events and about the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words, and other similar expressions. In addition, any statements that refer to projections of demand or supply trends, financial items, anticipated growth, future growth and revenues, future economic conditions and performance, plans, objectives and strategies for future operations, expectations, or other characterizations of future events or circumstances are forward-looking statements. All forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially from those implied by the forward-looking statements in this Quarterly Report are set forth in our 2022 Annual Report and include but are not limited to:

  • the effects of the COVID-19 pandemic or any future pandemic or health crisis on our business, financial condition and results of operations;
  • the duration and extent to which hospitals and other healthcare entities adjust their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market, economic conditions or COVID-19 pandemic;
  • the extent to which a spike in the COVID-19 pandemic may disrupt our operations due to the unavailability of our employees or healthcare professionals because of illness, risk of illness, quarantines, travel restrictions, mandatory vaccination requirements, desire to travel and work on temporary assignments or other factors that limit our existing or potential workforce and pool of candidates;
  • the severity and duration of the impact the COVID-19 pandemic, the Great Resignation, economic downturns, inflation, recession or slow recoveries have on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered;
  • the effects of economic downturns, inflation, recession or slow recoveries, which could result in less demand for our services, increased client initiatives designed to contain costs, including reevaluating their approach as it pertains to contingent labor and managed services programs;
  • any inability on our part to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs and requirements, including mandatory vaccination requirements;
  • the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts;
  • the level of consolidation and concentration of buyers of healthcare workforce, staffing and technology solutions, which could affect the pricing of our services and our ability to mitigate concentration risk;
  • the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, telemedicine or otherwise, and successfully hire and retain permanent staff, which may negatively affect our revenue, results of operations, and cash flows;
  • any inability on our part to recruit and retain sufficient quality healthcare professionals at reasonable costs, which could increase our operating costs and negatively affect our business and profitability;
  • any inability on our part to grow and operate our business profitably in compliance with federal and state regulation, including privacy laws, conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment and compensation practices and government contracting;
  • any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;
  • the effect of investigations, claims, and legal proceedings alleging medical malpractice, anti-competitive conduct, violations of employment, privacy and wage regulations and other legal theories of liability asserted against us, which could subject us to substantial liabilities;
  • any technology disruptions or our inability to implement new infrastructure and technology systems effectively may adversely affect our operating results and ability to manage our business effectively;
  • any failure to further develop and evolve our current workforce solutions technology offerings and capabilities, which may harm our business and/or impact our ability to compete with new technologies and competitors;
  • disruption to or failures of our SaaS-based or technology-enabled services, or our inability to adequately protect our intellectual property rights with respect to such technologies or sufficiently protect the privacy of personal information, could reduce client satisfaction, harm our reputation and negatively affect our business;
  • security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities;
  • any inability on our part to quickly and properly credential and match quality healthcare professionals with suitable placements, which may adversely affect demand for our services;
  • any inability on our part to continue to attract, develop and retain our sales and operations team members, which may deteriorate our operations;
  • our increasing dependence on third parties, including offshore vendors, for the execution of certain critical functions;
  • the loss of our key officers and management personnel, which could adversely affect our business and operating results;
  • any inability to consummate and effectively incorporate acquisitions into our business operations, which may adversely affect our long-term growth and our results of operations;
  • businesses we acquire may have liabilities or adverse operating issues, which could harm our operating results;
  • any increase to our business and operating risks as we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of client solutions;
  • any inability on our part to maintain our positive brand awareness and identity, which may adversely affect our results of operation;
  • the expansion of social media platforms presents new risks and challenges, which could cause damage to our brand reputation;
  • any recognition of an impairment to the substantial amount of goodwill or indefinite-lived intangibles on our balance sheet;
  • our indebtedness, which could adversely affect our ability to raise additional capital to fund operations, limit our ability to react to changes in the economy or our industry, and expose us to interest rate risk to the extent of any variable rate debt;
  • the terms of our debt instruments that impose restrictions on us that may affect our ability to successfully operate our business; and
  • the effect of significant adverse adjustments to our insurance-related accruals on our balance sheet, which could decrease our earnings or increase our losses and negatively impact our cash flows.

Market risk

As filed, 1,325 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates, and commodity prices. During the three and nine months ended September 30, 2023, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments and our investment portfolio. A 100 basis point increase in interest rates on our variable rate debt would not have resulted in a material effect on our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023. A 100 basis point change in interest rates as of September 30, 2023 would not have resulted in a material effect on the fair value of our investment portfolio. For our investments that are classified as available-for-sale, unrealized gains or losses related to fluctuations in market volatility and interest rates are reflected within stockholders’ equity in accumulated other comprehensive loss in the consolidated balance sheets. Such unrealized losses would be realized only if we sell the investments prior to maturity.

During the three and nine months ended September 30, 2023, we generated substantially all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.

Controls and procedures

As filed, 1,207 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 2023 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 501 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2022 Annual Report. The risk factors described in our 2022 Annual Report are not the only risks we face. Factors we currently do not know, factors that we currently consider immaterial or factors that are not specific to us, such as general economic conditions, may also materially adversely affect our business or our consolidated operating results, financial condition or cash flows.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-07-01 to 2023-09-30$853.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2023-01-01 to 2023-09-30$2.97bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-07-01 to 2023-09-30$564.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2023-01-01 to 2023-09-30$1.98bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-07-01 to 2023-09-30$289.5mus-gaap:GrossProfit
Gross profit9 months2023-01-01 to 2023-09-30$988.6mus-gaap:GrossProfit
Selling, general and administrative3 months2023-07-01 to 2023-09-30$163.4mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2023-01-01 to 2023-09-30$570.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-07-01 to 2023-09-30$86.9mus-gaap:OperatingIncomeLoss
Operating income9 months2023-01-01 to 2023-09-30$304.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-07-01 to 2023-09-30$11.5mus-gaap:InterestExpense
Interest expense9 months2023-01-01 to 2023-09-30$34.0mus-gaap:InterestExpense
Income tax3 months2023-07-01 to 2023-09-30$22.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2023-01-01 to 2023-09-30$72.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-07-01 to 2023-09-30$53.2mus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30$198.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30$1.39us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30$4.99us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30$1.39us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30$5.01us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-3038,325,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-3039,734,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30$413.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2023-01-01 to 2023-09-30$73.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2023-01-01 to 2023-09-30$424.7mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2023-09-30$29.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-09-30$831.1mus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$2.65bnus-gaap:Assets
Current liabilitiesAt period end2023-09-30$707.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$1.84bnus-gaap:Liabilities
Shareholders' equityAt period end2023-09-30$817.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001142750-23-000030. Last ingested by Listed: Nov 5, 2026, 17:59 ET. Listed shows no prices and gives no investment advice.